# Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

> **NCT05185258** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Aarhus University Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Psoriasis Vulgaris
- Psoriasis
- Skin Diseases
- Skin Diseases, Papulosquamous
- Skin and Connective Tissue Diseases

## Interventions

- **DRUG:** Enstilar
- **DRUG:** Placebo-vehicle

## Key facts

- **NCT ID:** NCT05185258
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-16
- **Primary completion:** 2024-01-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185258, "Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05185258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*